Wednesday, June 10, 2026

Drug profile · INN

mononuclear

mononuclear is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 3
Pipeline programs 12
News articles 0
Drug details — mononuclear
Class
Route
Patents
3
Programs
12
Data quality
0.70

Quick answer

mononuclear is an FDA-listed pharmaceutical active ingredient.

Key facts

INN mononuclear

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. Suspension of autologous mononuclear cells separated from bone marrow aspirate Phase 3 · George Institute for · diabetic foot syndrome, lower limb ischemia
  2. Autologous (self) mononuclear cells derived from umbilical cord blood Phase 2 · Regeneron Ireland Designated · Hypoplastic Left Heart Syndrome
  3. Autologous Bone Marrow Mononuclear Cells Phase 2 · Lxo Ireland Designated · Peripheral Vascular Diseases
  4. Autologous bone marrow mononuclear cell transplantation Phase 2 · UroGen Pharma · Spinal Cord Injury
  5. Bone marrow mononuclear cells Phase 2 · Lxo Ireland Designated · Chronic Myocardial Ischemia
  6. CMMo/RH/2009 Phase 2 · Lxo Ireland Designated · Liver Transplant Rejection
  7. Infusion of autologous mononuclear bone marrow cells Phase 2 · Lxo Ireland Designated · Idiopathic Dilated Cardiomyopathy
  8. Suspension of autologous mononuclear cells separated from bone marrow aspirate Phase 2 · George Institute for · chronic limb-threatening ischemia, diabetic foot ulcers

Related patents

  1. US 12264322

    Minimal volume reprogramming of mononuclear cells

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 10954529

    Minimal volume reprogramming of mononuclear cells

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 10023879

    Minimal volume reprogramming of mononuclear cells

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is mononuclear?

mononuclear is an FDA-listed pharmaceutical active ingredient.